Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at Oxford University have been awarded a £6 million grant for their cutting-edge research programme on finding drug targets for Parkinson's Disease.

This new funding builds on an initial £5M investment from Parkinson’s UK to researchers at the Oxford Parkinson’s Disease Centre (OPDC) in 2010.

One in 500 people in Oxfordshire have Parkinson's – a neurological condition which can leave people struggling to walk, speak and sleep, and which has no cure.

By 2020 the multidisciplinary team at Oxford hopes to use the £6 million to find new drugs to slow, or even stop Parkinson's, using a 'brain cell bank' they have developed to identify promising new drug targets. They also want to improve how to diagnose and monitor Parkinson's using new technology, such as smartphone apps.

In the last five years, the team has developed one of the largest studies of people living with Parkinson's anywhere in the world, leading to progress in understanding why brain cells die and in detecting early changes in patients before full symptoms occur. Working with Thames Valley patients the team have created a tool to detect early stage Parkinson's with 85% accuracy using brain imaging.

Professor Richard-Wade Martins, lead researcher at the OPDC, said of receiving the funding: 'In the last five years we've made remarkable progress. We've built a study integrating work in the clinic and the laboratory like nowhere else in the world. Alongside this, our program to change cells from patients' skin into brain cells using cutting-edge stem cell technology has allowed us to gain completely new insights about Parkinson's and how it develops.

We’re delighted the new funding from Parkinson’s UK will secure the future of this and other vital projects.'

Read more

                   

Similar stories

Thomas Willis (1621 - 1675) 400th Birthday - Alastair Buchan in conversation with Zoltán Molnár

General Research

Professor Zoltán Molnár talks to Pro-Vice-Chancellor Professor Alastair Buchan to learn more about Thomas Willis's residence and base for scientific discoveries, Beam Hall.

Thomas Willis (1621 - 1675) 400th Birthday - Erica Charters in conversation with Zoltán Molnár

General Research

Professor Zoltán Molnár talks to Dr Erica Charters for a History of Medicine perspective on Oxford physician and Father of Neurology Thomas Willis.

Thomas Willis 400th anniversary trailer

General Research

On 27 January 2021 we celebrate the 400th anniversary of the birth of the greatest neuroanatomist of all time, Thomas Willis. DPAG's Professor Zoltán Molnár has interviewed 8 experts - watch a video preview of what's to come from Monday onwards! With thanks to St John's College.

Earliest origins of the forming heart identified

Cardiac Theme Postdoctoral Publication Research

The earliest known progenitor of the outermost layer of the heart has been characterised for the first time and linked to the development of other critical cell types in the developing heart in a new paper from the Srinivas group led by BHF Immediate Fellow Dr Richard Tyser.

Lukas Krone to represent Oxford at the Global Young Scientists Summit

Awards and Honours EDI News Head of Department's News Students Vyazovskiy Group News

Congratulations are in order for Dr Lukas Krone who is one of just five University of Oxford researchers selected to attend the Global Young Scientists Summit 2021.

Covid-19 lung damage identified in study

Postdoctoral Research

In a new study into the longer-term damage amongst patients recovering from COVID-19, DPAG Research Fellow Dr James Grist of the Tyler Lab has been running a novel scanning technique that shows a dramatic decrease in the ability of the lungs to diffuse gas in to the blood stream after COVID infection. This work may shed light on the problem of breathlessness after COVID infection and help guide us in understanding therapeutic selection and efficacy.